Brain Imaging of Cognition Inn Schizophrenia and Depression
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorThe Royal Ottawa Mental Health Centre
About this trial
Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining employment or academic activity. Moreover, cognitive difficulties tend to persist even after the stabilization of other clinical symptoms. Verbal memory and emotion regulation are two important cognitive domains that are impaired in schizophrenia and depression and are associated with patients' functional outcomes. In this study, brain imaging is used to investigate the brain mechanisms underlying these cognitive deficits in these populations.
Eligibility criteria
Qualifiers
age 18-60 years
current Intelligence Quotient (IQ) > 70 as measured by the Wechsler Abbreviated Scale of Intelligence (WASI)
the ability to read and speak fluent English
a diagnosis of schizophrenia, schizoaffective or major depression disorder
Disqualifiers
significant neurological or other medical disorders that may produce cognitive impairment
a recent history of substance abuse or dependence (within the past 3 months)
any magnetic resonance imaging (MRI) contraindications (e.g. metallic head implant, history of seizure, pacemaker)
decisional incapacity requiring a guardian
Trial design
Treatments tested in this trial
- Not listed
Trial groups
90 Participants
are grouped into 3 trial groupsSponsors and collaborators
Source ClinicalTrials.gov